SpringerLink
Log in

Unlocking the concealed targets using system biology map** for Alzheimer’s disease

  • Short communication
  • Published:
Pharmacological Reports Aims and scope Submit manuscript

Abstract

Background

Alzheimer’s disease (AD) constitutes a neural loss in histology of brain with involvement of complex genomic and environmental factors. Accumulation of amyloid beta (Aβ) peptide and phosphorylated tau are indicative of progression and cognitive decline. Hence an understanding of the underlying biological pathways and targets along with associated mechanisms would be useful for the development of improved therapeutics for treating AD. In the present work, we aim to identify concealed targets for develo** first line therapeutics and repositioning of validated targets as well as FDA- approved drugs using a system biology approach.

Methods

We have collated information pertaining to the biological targets as well as the approved drugs, from scientific literature and patents.

Results

In all, the imbalance in the functioning of around 79 proteins and genes were identified to be involved in Alzheimer’s cascade. Amongst them, around 21 targets were found to be under therapeutic consideration for AD. Of the remaining, around 17 targets were reported as potential targets for AD, although they are under researcher’s attention for other physio-pathological conditions. The analysis further revealed that −41 therapeutic targets are pharmacologically concealed but structurally validated targets and may constitute as potential therapeutic candidate for future drug discovery for AD.

Conclusion

The biological pathway vs. drug map** provides a complete overview about underlying biological pathways, therapeutic targets (explored and concealed), associated mechanisms, existing therapeutics and the information pertaining to molecules currently under active drug development for further drug discovery and drug re-positioning/repurposing approaches for AD management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Verma S, Prabhakar YS. Target based drug design-a reality in virtual sphere. Curr Med Chem 2015;22(13):1603–30.

    Article  CAS  PubMed  Google Scholar 

  2. Lusher SJ, McGuire R, van Schaik RC, Nicholson CD, de Vlieg J. Data-driven medicinal chemistry in the era of big data. Drug Discov Today 2014;19(7):859–68.

    Article  CAS  PubMed  Google Scholar 

  3. Apic G, Ignjatovic T, Boyer S, Russell RB. Illuminating drug discovery with biological pathways. FEBS Letters (Amsterdam) 2005;579(8):1872–7.

    Article  CAS  Google Scholar 

  4. Ganguli M, Age Rodriguez E. Alzheimer’s disease, and the big picture. Int Psychogeriatr 2011;23(10):1531–4.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Cummings JL, Vinters HV, Cole GM, Khachaturian ZS. Alzheimer’s disease Etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998;1(51):S2–17.

    Article  Google Scholar 

  6. Sanderson WC, Scherbov S. Faster increases in human life expectancy could lead to slower population aging. PLoS One 2015;10(4)e0121922 15.

    Article  Google Scholar 

  7. Power R, Prado-Cabrero A, Mulcahy R, Howard A, Nolan JM. The role of nutrition for the aging population: implications for cognition and Alzheimer’s disease. Annu Rev Food Sci Technol 2019;10:619–39.

    Article  CAS  PubMed  Google Scholar 

  8. Chételat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, et al. Relationship between atrophy and β-amyloid deposition in Alzheimer disease. Ann Neurol 2010;67(3):317–24.

    PubMed  Google Scholar 

  9. Richard M, Sano M. Treatment of Alzheimer’s disease. N Engl J Med 1999;341(22):1670–9.

    Article  Google Scholar 

  10. Beason-Held L, Goh J, An Y, Kraut M, O’Brien R, Ferrucci L, et al. Changes in brain function occur years before the onset of cognitive impairment. J Neurosci 2013;33(46):18008–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Swerdlow R. Pathogenesis of Alzheimer’s disease. Clin Interv Aging 2007;2(3):347.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Mohandas E, Rajmohan V, Raghunath B. Neurobiology of Alzheimer’s disease. Indian J Psychiatry 2009;51(1):55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lanctôt KL, Amatniek J, Ancoli-Israel S, Arnold SE, Ballard C, Cohen-Mansfield J, et al. Neuropsychiatric signs and symptoms of Alzheimer’s disease: new treatment paradigms. Alzheimers Dement (N Y) 2017;3(3):440–9.

    Article  PubMed  Google Scholar 

  14. Mattson MP. Pathways towards and away from Alzheimer’s disease. Nature 2004;430(7000):631.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Bancher C, Brunner C, Lassmann H, Budka H, Jellinger K, Wiche G, et al. Accumulation of abnormally phosphorylated τ precedes the formation of neurofibrillary tangles in Alzheimer’s disease. Brain Res 1989;477(1–2) 90–9 16.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CSIR - Unit for Research and Development of Information Products (URDIP), Pune, Maharashtra, India

    Poorvashree Joshi, Vikram Kawade & Sivakami Dhulap

  2. Solution Consultant, Clarivate Analytics, Bengaluru Karnataka, India

    Mandakini Goel

Authors
  1. Poorvashree Joshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vikram Kawade
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sivakami Dhulap
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mandakini Goel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sivakami Dhulap.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Joshi, P., Kawade, V., Dhulap, S. et al. Unlocking the concealed targets using system biology map** for Alzheimer’s disease. Pharmacol. Rep 71, 1104–1107 (2019). https://doi.org/10.1016/j.pharep.2019.06.012

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.pharep.2019.06.012

Keywords

Search

Navigation